The addition of cixutumumab to androgen deprivation therapy did not significantly increase the undetectable PSA rate in patients with new metastatic hormone-sensitive prostate cancer, according to results of a randomized phase 2 study.Previous studies of cixutumumab (IMC-A12, ImClone Systems) — which targets the insulin-like growth factor I receptor (IGF-IR) — have demonstrated biologic and clinical activity in men undergoing treatment for prostate cancer, according to study background.
No comments:
Post a Comment